Investing in Anti-HIV

Antiretroviral therapy (ART) remains highly effective and well‑tolerated when taken as prescribed. But, it requires lifelong adherence and consistent access, as it does not induce protective immunity or cure HIV. Since the mid‑2000s, public‑health initiatives that expand tailored ART access have successfully curbed HIV in low‑resource settings and among marginalised populations at highest risk.

This progress, however, is fragile. It depends on sustained, coordinated global investment. Interruptions in ART availability can trigger surges in new infections and the emergence of drug‑resistant strains. To strengthen epidemic control, therapeutic developers must advance new methods of prevention and treatment that simplify public‑health delivery and demonstrate reliable performance under real‑world conditions.

Download whitepaper to learn:

• Enduring challenges to HIV therapeutic control faced by therapeutic developers:

  • Biological mechanisms that sustain persistent infection and transmission

  • Behavioral and sociocultural factors that can jeopardise real-world efficacy

• Recent innovations in HIV therapeutic development

  • Long‑acting injectable ART

  • Vaccines for protective immunity

  • Curative strategies

• Best practices for designing HIV therapies and trials that reflect post‑approval realities

  • Investment in supportive diagnostics and digital health technologies

  • Trial designs that capture demographic‑specific barriers to efficacy

  • Engagement with community partnerships

  • Minimally burdensome trial designs